title: Highlights from the International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, And Clinical Applications, Philadelphia, PA, November 2005; ECCO 13--The European Cancer Conference, Paris, France, October 30-November 3, 2005.
authors.forename: Kesava
authors.initials: K
authors.lastname: Reddy
authors.forename: Amy
authors.initials: A
authors.lastname: D'Orazio
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D016547:Kinesins / Q000037:antagonists & inhibitors; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D011799:Quinazolines / Q000627:therapeutic use; D014747:Vinblastine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001549:Benzamides; D011799:Quinazolines; D000068258:Bevacizumab; C111217:vinflunine; D014747:Vinblastine; C508757:ispinesib; D000069347:Erlotinib Hydrochloride; D016547:Kinesins